Document is current
Any future updates will be listed below
-
Authors
Stein, Mark N.
Malhotra, Jyoti
Tarapore, Rohinton S.
Malhotra, Usha
Silk, Ann W.
Chan, Nancy
Rodriguez, Lorna
Aisner, Joseph
Aiken, Robert D.
Mayer, Tina
Haffty, Bruce G.
Newman, Jenna H.
Aspromonte, Salvatore M.
Bommareddy, Praveen K.
Estupinian, Ricardo
Chesson, Charles B.
Sadimin, Evita T.
Li, Shengguo
Medina, Daniel J.
Saunders, Tracie
Frankel, Melissa
Kareddula, Aparna
Damare, Sherrie
Wesolowsky, Elayne
Gabel, Christian
El-Deiry, Wafik S.
Prabhu, Varun V.
Allen, Joshua E.
Stogniew, Martin
Oster, Wolfgang
Bertino, Joseph R.
Libutti, Steven K.
Mehnert, Janice M.
Zloza, Andrew http://orcid.org/0000-0001-8844-6493
-
Funding
Funding for this research was provided by:
Oncoceutics (-)
- License Information
-
More Information
Article History
Received: 20 December 2018
Accepted: 23 April 2019
First Online: 22 May 2019
Ethics approval and consent to participate
: All patients provided written informed consent. The study was performed in accordance with a protocol approved by the IRB at Rutgers, The State University of New Jersey, in accordance with the ethical principles originating in the Declaration of Helsinki, and was consistent with International Conference on Harmonization/Good Clinical Practice guidelines and applicable regulatory requirements.
: Not applicable.
: Rohinton S. Tarapore, Varun V. Prabhu, Joshua E. Allen, Martin Stogniew, and Wolfgang Oster are employees and shareholders of Oncoceutics. Joseph Bertino is a shareholder of Oncoceutics. Wafik S. El-Deiry is the Scientific Founder of Oncoceutics and a shareholder and is compliant with institutional and NIH guidelines for disclosure of conflict of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
